CompletedPhase 2NCT01753713

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Manmeet Ahluwalia, MD
Principal Investigator
Manmeet Ahluwalia, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Intervention
dovitinib(drug)
Enrollment
33 enrolled
Eligibility
18 years · All sexes
Timeline
20122017

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01753713 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials